KATARINA STENKLO
Global FlexFactory Product Manager, Cytiva, Uppsala, Sweden

Abstract

For emerging mRNA-based drugs that can sometimes require small, intensified batches, paperless manufacturing—using automated, digital data management instead of paper-based recordkeeping—offers even more competitive advantages. In this article, we address the benefits of paperless manufacturing to both small and emerging companies alike, why it’s essential to incorporate a digital strategy early in the manufacturing process, and how a digital solution for mRNA manufacturing can help small batch manufacturers more effectively produce these soon-to-be essential medicines.

Digital technologies like artificial intelligence (AI), big data, cloud computing, the Internet of Things (IoT), and application programming interfaces (APIs) are predicted to increasingly impact the biopharma industry in the next few years (1, 2). The question for manufacturers is, are they ready to embrace the changes?

Whether implementing more advanced automation, building out smart plants, or moving toward paperless manufacturing, improving the level of digital maturity within drug manufacturing processes can reduce costs, save time, and mitigate risk. For emerging mRNA-based drugs that can sometimes require small, intensified batches, paperless manufacturing—using automated, digital data management instead of paper-based recordkeeping—offers even more competitive advantages. In this article, we address the benefits of paperless manufacturing to both small and emerging companies alike, why it’s essential to incorporate a digital strategy early in the manufacturing process, and how a digital solution for mRNA manufacturing can help small batch manufacturers more effectively produce these soon-to-be essential medicines.